SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...
-- Clinical Trial and Clinical Pharmacology Data Support Upcoming Enrollment of Omeros’ Zaltenibart Phase 3 Clinical Program in PNH -- Morag Griffin, MBChB, FRCPath, Consultant in Haematology of St.
In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, severe, and potentially life-threatening condition. Treatments targeting the complement pathway have revolutionized its management but have ...
Dr De Castro provides an overview of IV versus oral therapies for patients with PNH. Carlos M. De Castro, MD: If you look at complements, they’re activated in 3 ways. There’s the classical pathway, an ...
Iptacopan treatment on top of standard of care resulted in significant and clinically meaningful reductions in proteinuria compared with placebo in patients with complement 3 glomerulopathy. Results ...
The European Medicines Agency (EMA) has granted a marketing authorization to Novartis Europharm for Fabhalta (iptacopan) for treating adults with paroxysmal nocturnal hemoglobinuria (PNH) who have ...
Researchers from Kira Pharmaceuticals LLC and University of Pennsylvania have developed a novel mouse model of rapidly progressing lethal C3 glomerulopathy (C3G), with the aim of assessing whether ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback